1. Title of Derivative Security (Instr. 4) |
2. Date Exercisable and Expiration Date (Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |
4. Conversion or Exercise Price of Derivative Security |
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |
6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Employee Stock Option (Right to Buy)
|
Â
(1)
|
03/31/2024 |
Common Stock
|
60,000
|
$
11.3
|
D
|
Â
|
Employee Stock Option (Right to Buy)
|
Â
(2)
|
01/06/2025 |
Common Stock
|
29,000
|
$
39.94
|
D
|
Â
|
Employee Stock Option (Right to Buy)
|
Â
(3)
|
01/05/2026 |
Common Stock
|
20,000
|
$
8.47
|
D
|
Â
|
Employee Stock Option (Right to Buy)
|
Â
(4)
|
01/29/2027 |
Common Stock
|
50,000
|
$
3.69
|
D
|
Â
|
Restricted Stock Units
|
Â
(5)
|
Â
(5)
|
Common Stock
|
8,000
|
$
(6)
|
D
|
Â
|
* |
If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** |
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) |
This option vests over four years. Twenty-five percent (25%) of the shares vested on April 1, 2015 and 6.25% of the shares will vest at the end of each successive three-month period thereafter. |
(2) |
Vests as to 6.25% of the shares on 4/7/2015 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/7/2019. |
(3) |
Vests as to 6.25% of the shares on 4/6/2016 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/6/2020. |
(4) |
Vests as to 6.25% of the shares on 4/30/2017 and further vests as to an additional 6.25% of the original grant at the end of each successive three-month period thereafter until 1/30/2021. |
(5) |
The restricted stock units vest in three equal installments on each of January 6, 2017, January 6, 2018 and January 6, 2019. |
(6) |
Each restricted stock unit represents a contingent right to receive one share of common stock of Tetraphase Pharmaceuticals, Inc. for no consideration. |